Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization
- PMID: 2251875
- DOI: 10.1016/0264-410x(90)90253-i
Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization
Abstract
Formalin-inactivated (FI) RSV, purified F glycoprotein in alum, and RSV infection (intranasal) were compared for their immunogenicity, efficacy, and ability to enhance pulmonary histopathology during RSV infection 3 and 6 months following immunization by the intramuscular route. Purified influenza virus in alum was used as a control immunogen. At 1 month following immunization with one dose of purified F glycoprotein (5 micrograms), cotton rats developed levels of F antibodies (ELISA) higher than the other groups, but these antibodies had the lowest level of neutralizing activity, Little increase in antibody titre was seen following a second dose of FI-RSV or purified F vaccine given at 1 month. Animals that received 5 micrograms F, 0.5 microgram F, or were almost completely resistant to pulmonary RSV infection following challenge at 3 months, but were susceptible by 6 months. Animals immunized with 5 micrograms of purified F glycoprotein developed alveolar and bronchiolar histopathology following RSV challenge at 3 or 6 months which was comparable to that of animals immunized with FI-RSV. These levels significantly exceeded those in animals previously immunized with influenza A virus vaccine which exhibited little histopathology. Animals previously infected with RSV also developed bronchiolar, but not alveolar, histopathology suggesting that the bronchiolar histopathology seen in RSV challenged cotton rats is a normal component of the immune resolution of RSV infection. These results suggest that the immune response of cotton rats to immunoaffinity purified F glycoprotein can result in enhanced bronchiolar and alveolar histopathology following RSV challenge. Thus, caution should be exercised in studies in humans using a purified F glycoprotein subunit vaccine.
Comment in
-
Immunogen-induced enhanced pulmonary histopathology in the RSV cotton rat model.Vaccine. 1993;11(6):689-90. doi: 10.1016/0264-410x(93)90328-u. Vaccine. 1993. PMID: 8322496 No abstract available.
Similar articles
-
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.
-
Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.Virus Res. 1988 Aug;11(1):1-15. doi: 10.1016/0168-1702(88)90063-9. Virus Res. 1988. PMID: 2845680 Review.
-
Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.Vaccine. 1989 Dec;7(6):533-40. doi: 10.1016/0264-410x(89)90278-8. Vaccine. 1989. PMID: 2692334
-
Detection of respiratory syncytial virus (RSV) infected cells by in situ hybridization in the lungs of cotton rats immunized with formalin-inactivated virus or purified RSV F and G glycoprotein subunit vaccine and challenged with RSV.Virus Res. 1990 Jun;16(2):153-62. doi: 10.1016/0168-1702(90)90019-8. Virus Res. 1990. PMID: 2385958
-
Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.Vaccine. 1992;10(7):475-84. doi: 10.1016/0264-410x(92)90397-3. Vaccine. 1992. PMID: 1609551
Cited by
-
Intranasal respiratory syncytial virus vaccine attenuated by codon-pair deoptimization of seven open reading frames is genetically stable and elicits mucosal and systemic immunity and protection against challenge virus replication in hamsters.PLoS Pathog. 2024 May 13;20(5):e1012198. doi: 10.1371/journal.ppat.1012198. eCollection 2024 May. PLoS Pathog. 2024. PMID: 38739647 Free PMC article.
-
Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein.PLoS One. 2024 Apr 9;19(4):e0301773. doi: 10.1371/journal.pone.0301773. eCollection 2024. PLoS One. 2024. PMID: 38593167 Free PMC article.
-
Diversity and evolution of computationally predicted T cell epitopes against human respiratory syncytial virus.PLoS Comput Biol. 2023 Jan 10;19(1):e1010360. doi: 10.1371/journal.pcbi.1010360. eCollection 2023 Jan. PLoS Comput Biol. 2023. PMID: 36626370 Free PMC article.
-
Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2.NPJ Vaccines. 2022 Jun 28;7(1):72. doi: 10.1038/s41541-022-00493-x. NPJ Vaccines. 2022. PMID: 35764659 Free PMC article.
-
Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses.Front Immunol. 2022 Apr 4;13:882972. doi: 10.3389/fimmu.2022.882972. eCollection 2022. Front Immunol. 2022. PMID: 35444667 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources